Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA

Xenobiotica

Volumn 43, Issue 10, 2013, Pages 920-931

  Williamson, B ^a   Soars, A C ^b   Owen, A ^a   White, P ^b   Riley, R J ^b   Soars, M G ^b,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cytochrome P450; Drug transporters; Drug drug interactions; Hepatocytes; OATP1B1; Organic anion polypeptides; Pharmacokinetics; SiRNA

Indexed keywords

ATORVASTATIN; CELL NUCLEUS RECEPTOR; DRUG METABOLIZING ENZYME; ESTRONE SULFATE; ISOPROTEIN; LIPID; LOPINAVIR; MESSENGER RNA; OLMESARTAN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PITAVASTATIN; ROSUVASTATIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VALSARTAN; XENOBIOTIC AGENT;

ARTICLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOPRESERVATION; HORMONE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIVER CELL; METHODOLOGY; PEPTIDE ANALYSIS; PROTEIN EXPRESSION; REACTION OPTIMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSPORT;

BASE SEQUENCE; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ESTRONE; FEMALE; FLUOROBENZENES; HEPATOCYTES; HUMANS; IMIDAZOLES; MALE; MOLECULAR SEQUENCE DATA; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; QUINOLINES; RNA, SMALL INTERFERING; SULFONAMIDES; TETRAZOLES; VALINE; XENOBIOTICS;

EID: 84881339287     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.776194     Document Type: Article

References (50)

1. Aleku M, Schulz P, Keil O, et al. (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68:9788-98
2. Asberg A, Hartmann A, Fjeldsa E, et al. (2001). Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382-6 (Pubitemid 33681704)
3. Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant Br J Clin Pharmacol 60:508-18 (Pubitemid 41532451)
4. Cui Y, Konig J, Leier I, et al. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-30
5. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-53 (Pubitemid 47064567)
6. Degorter MK, Ho RH, Leake BF, et al. (2012). Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. Mol Pharm 9:986-95
7. Fire A, Xu S, Montgomery MK, et al. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-11 (Pubitemid 28099681)
8. Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801
9. Hartkoorn RC, Kwan WS, Shallcross V, et al. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20:112-20
10. Hedman M, Neuvonen PJ, Neuvonen M, et al. (2004). Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 75:101-9 (Pubitemid 38130122)
11. Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-46 (Pubitemid 39287793)
12. Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1 Drug Metab Dispos 34:1229-36
13. Ieiri I, Suwannakul S, Maeda K, et al. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541-7 (Pubitemid 47622520)
14. Jones HM, Barton HA, Lai Y, et al. (2012). Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-17
15. Karlgren M, Vildhede A, Norinder U, et al. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions J Med Chem 55:4740-63
16. Kitamura S, Maeda K, Wang Y, Sugiyama Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-23
17. Kotani N, Maeda K, Watanabe T, et al. (2011). Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos 39:1503-10
18. Kullak-Ublick GA, Ismair MG, Stieger B, et al. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120: 525-33 (Pubitemid 32147650)
19. Liao M, Raczynski AR, Chen M, et al. (2010). Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions Drug Metab Dispos 38: 1612-22
20. Maeda K, Ieiri I, Yasuda K, et al. (2006). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79: 427-39
21. McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463-79 (Pubitemid 47603410)
22. Miyagawa M, Maeda K, Aoyama A, Sugiyama Y. (2009). The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17beta-D-glucuronide. J Pharmacol Exp Ther 329:551-7
23. Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-81 (Pubitemid 44908269)
24. Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-81
25. Noe J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308-14 (Pubitemid 47121771)
26. Olbricht C, Wanner C, Eisenhauer T, et al. (1997). Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62: 311-21 (Pubitemid 27417797)
27. Paine SW, Parker AJ, Gardiner P, et al. (2008). Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365-74 (Pubitemid 351929321)
28. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-33 (Pubitemid 350114817)
29. Poirier A, Cascais AC, Funk C, Lave T. (2009). Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 36:585-611
30. Poirier A, Lave T, Portmann R, et al. (2008). Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos 36:2434-44
31. Regazzi MB, Iacona I, Campana C, et al. (1993). Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732-4 (Pubitemid 23239614)
32. Riley RJ. (2001). The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Devel 4:45-54 (Pubitemid 32118458)
33. Santel A, Aleku M, Keil O, et al. (2006a). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 16:1222-34 (Pubitemid 44184716)
34. Santel A, Aleku M, Keil O, et al. (2006b). RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 18:1360-70 (Pubitemid 44323692)
35. Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-46 (Pubitemid 43363338)
36. Simonson SG, Raza A, Martin PD, et al. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-77 (Pubitemid 39013406)
37. Soars, MG, Barton P, Ismair M, et al. (2012). The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos 40:1641-8
38. Soars MG, Grime K, Sproston JL, et al. (2007a). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859-65 (Pubitemid 46798596)
39. Soars MG, McGinnity DF, Grime K, Riley RJ. (2007b). The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2-15 (Pubitemid 46661937)
40. Soars MG, Webborn PJ, Riley RJ. (2009). Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry Mol Pharm 6:1662-77
41. Suwannakul S, Ieiri I, Kimura M, et al. (2008). Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet 53:899-904
42. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. (2010). A status report on RNAi therapeutics. Silence 1:1-13, Article no. 14
43. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. (1998). Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharm Sci 87:845-53 (Pubitemid 28319415)
44. Watanabe T, Kusuhara H, Debori Y, et al. (2011). Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments Drug Metab Dispos 39:1031-8
45. Watanabe, T, Kusuhara H, Maeda K, et al. (2010). Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38: 215-22
46. Yabe Y, Galetin A, Houston JB. (2011). Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808-14
47. Yamada A, Maeda K, Kamiyama E, et al. (2007). Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166-76 (Pubitemid 350146202)
48. Yamashiro W, Maeda K, Hirouchi M, et al. (2006). Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247-54
49. Yu AM. (2007). Small interfering RNA in drug metabolism and transport. Curr Drug Metab 8:700-8
50. Yue W, Abe K, Brouwer KL. (2009). Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm 6:134-43.